Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymphoproliferative disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    50 result(s) found for: Lymphoproliferative disease. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2013-004479-11 Sponsor Protocol Number: DPTLDSG-IIT-PTLD-2 Start Date*: 2014-09-19
    Sponsor Name:DIAKO Ev. Diakonie-Krankenhaus Bremen gGmbH
    Full Title: Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With 4 Courses of Rituximab SC Followed by 4 Courses of Rituximab SC, 4 Courses of Rituximab SC Combined W...
    Medical condition: Previously untreated CD20-positive lymphoproliferative disorder (PTLD) following solid organ transplantation
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051358 Post transplant lymphoproliferative disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005454-35 Sponsor Protocol Number: RG_15-235 Start Date*: 2016-09-23
    Sponsor Name:University of Birmingham
    Full Title: Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)
    Medical condition: Post-transplant lymphoproliferative disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051358 Post transplant lymphoproliferative disorder PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-002949-30 Sponsor Protocol Number: ATA129-EBV-302 Start Date*: 2020-07-17
    Sponsor Name:Atara Biotherapeutics, Inc.
    Full Title: Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative D...
    Medical condition: Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068349 Epstein-Barr virus associated lymphoproliferative disorder PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075146 Post transplant Epstein-Barr virus associated lymphoproliferative disorder LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004657-11 Sponsor Protocol Number: VI-Plt-01 Start Date*: 2012-03-30
    Sponsor Name:FONDAZIONE PROGETTO EMATOLOGIA
    Full Title: Open label multicenter study of Eltrombopag for the treatment of Immune ThrombocytoPenia (ITP) secondary to Chronic Lymphoproliferative Disorders (LPDs)
    Medical condition: Immune ThrombocytoPenia (ITP) secondary to Chronic Lymphoproliferative Disorders (LPDs)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10005329 - Blood and lymphatic system disorders 10050245 Autoimmune thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003983-28 Sponsor Protocol Number: SGN35-028 Start Date*: 2020-11-27
    Sponsor Name:SEAGEN INC.
    Full Title: A phase 2, multicenter, single-arm study of retreatment with brentuximab vedotin in subjects with relapsed or refractory classic Hodgkin lymphoma (cHL) or CD30-expressing peripheral T cell lymphoma...
    Medical condition: - classic Hodgkin lymphoma (cHL) - Systemic anaplastic large cell lymphoma (sALCL) - CD30-expressing peripheral T cell lymphoma (PTCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073478 Anaplastic large-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020328 Hodgkin's lymphoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034623 Peripheral T-cell lymphoma unspecified PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034624 Peripheral T-cell lymphoma unspecified NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001412 Adult T-cell leukemia-lymphoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065855 Extranodal NK/T-cell lymphoma, nasal type LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073481 Enteropathy-associated T-cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022703 Intestinal T-cell lymphoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061232 Lymphoproliferative disorder PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066957 Hepatosplenic T-cell lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002449 Angioimmunoblastic T-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042971 T-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003982-17 Sponsor Protocol Number: SGN35-015 Start Date*: 2020-10-21
    Sponsor Name:SEATTLE GENETICS, INC.
    Full Title: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant...
    Medical condition: • Hodgkin lymphoma (HL) • CD30-expressing peripheral T-cell lymphoma (PTCL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020328 Hodgkin's lymphoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034623 Peripheral T-cell lymphoma unspecified PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034624 Peripheral T-cell lymphoma unspecified NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073478 Anaplastic large-cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001412 Adult T-cell leukemia-lymphoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065855 Extranodal NK/T-cell lymphoma, nasal type LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073481 Enteropathy-associated T-cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022703 Intestinal T-cell lymphoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061232 Lymphoproliferative disorder PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066957 Hepatosplenic T-cell lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002449 Angioimmunoblastic T-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042971 T-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000177-25 Sponsor Protocol Number: ATA129-EBV-205 Start Date*: 2021-01-04
    Sponsor Name:Atara Biotherapeutics, Inc.
    Full Title: An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases
    Medical condition: • EBV+ primary imunodeficiency lymphoproliferative disease (LPD) • EBV+ LPD in the setting of acquired (non-congenital) immunodeficiency • EBV+ post-transplant LPD involving the central nervous ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068349 Epstein-Barr virus associated lymphoproliferative disorder PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002989-33 Sponsor Protocol Number: COLPRIT-0000-BAS-0041-I Start Date*: 2023-06-29
    Sponsor Name:Klinikum rechts der Isar der Technischen Universität München
    Full Title: CHEMOKINE RECEPTOR CXCR4-DIRECTED THERANOSTICS OF ADVANCED LYMPHOPROLIFERATIVE CANCERS BY RADIOPEPTIDE-BASED IMAGING AND THERAPY: THE COLPRIT PHASE I/II STUDY
    Medical condition: Indication: Non-Hodgkin lymphomas (NHL) Advanced lymphoproliferative cancers: aggressive B- and T- cell Non-Hodgkin lymphomas (NHL), including heavily pretreated transformed indolent lymphoma (tNHL...
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004105-28 Sponsor Protocol Number: 291-420 Start Date*: 2006-06-20
    Sponsor Name:PDL BioPharma, Inc.
    Full Title: An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis.
    Medical condition: Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC).
    Disease: Version SOC Term Classification Code Term Level
    8.0 10045265 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended) NL (Ongoing) GR (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006373-25 Sponsor Protocol Number: A3921029 Start Date*: 2007-03-23
    Sponsor Name:Pfizer, S.A.
    Full Title: ESTUDIO OBSERVACIONAL PROSPECTIVO PARA EVALUAR LA SEGURIDAD A LARGO PLAZO Y EL ESTADO FUNCIONAL DE SUJETOS CON ARTRITIS REUMATOIDE INCLUIDOS PREVIAMENTE EN ESTUDIOS DE CP-690,550 A PROSPECTIVE OBS...
    Medical condition: CP-690,550 se está desarrollando como fármaco antirreumático modificador de la enfermedad (FARME) para el tratamiento de la artritis reumatoide (AR). CP 690,550 is being developed as a disease mo...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) SE (Completed) SK (Completed) CZ (Completed) GR (Completed) DE (Completed) FI (Completed) BG (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004835-30 Sponsor Protocol Number: CAD5 Start Date*: 2012-10-23
    Sponsor Name:Department of Medicine, Haugesund Hospital
    Full Title: Therapy for chronic cold agglutinin disease: A prospective, non-randomized international multicenter trial on the safety and efficacy of bendamustine and rituximab combination therapy.
    Medical condition: Primary chronic cold agglutinin disease requiring treatment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) DK (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2008-006713-25 Sponsor Protocol Number: ASSENTE Start Date*: 2008-09-23
    Sponsor Name:OSPEDALE MAGGIORE DI MILANO (IRCCS)
    Full Title: A SINGLE-ARM PILOT STUDY WITH LOW-DOSE RITUXIMAB PLUS STANDARD ORAL PREDNISONE IN IDIOPATHIC AUTOIMMUNE HEMOLYTIC ANEMIA
    Medical condition: ANEMIE EMOLITICHE AUTOIMMUNI IDIOPATICHE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011817-26 Sponsor Protocol Number: BHS-UCB2009 Start Date*: 2010-10-21
    Sponsor Name:UZ Brussel VUB
    Full Title: A pilot study to assess the feasibility of unrelated umbilical cord blood transplantation with coinfusion of third-party mesenchymal stem cells after myeloablative or nonmyeloablative conditioning ...
    Medical condition: Adult patients with hematological malignancies
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000720-17 Sponsor Protocol Number: MOM-M281-006 Start Date*: 2020-01-14
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled Study with a Long-term Open-label Extension
    Medical condition: Adults with Warm Autoimmune Hemolytic Anemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004851 10002285 Anemia hemolytic autoimmune (NOS) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Temporarily Halted) HU (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-001563-21 Sponsor Protocol Number: IM-T-hLL2-18 Start Date*: 2005-02-02
    Sponsor Name:Immunomedics, Inc.
    Full Title: A Phase II, Single-Arm Trial of Naked Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients with Waldenström's Macroglobulinemia
    Medical condition: Waldenström's Macroglobulinemia (WM) is an uncommon B-cell lymphoproliferative disorder that predominantly involves older patients with a slight male preponderance. WM resembles myeloma and chroni...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002971-42 Sponsor Protocol Number: PEG-HSR Start Date*: 2006-06-19
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: Outpatients high-dose chemotherapy supported by autologus peripheral blood stem and single-dose pegfilgrastim in patients with lymphoproliferative malignances.
    Medical condition: patients affected by linphoproliferative pathologies
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 Blood and lymphatic system disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004102-15 Sponsor Protocol Number: 0468H-102012 Start Date*: 2015-04-06
    Sponsor Name:Wyeth
    Full Title: An open label comparative study of de novo renal allograft recipients receiving CsA + MMF + corticosteroids versus CsA + Rapamune + corticosteroids with further CsA elimination in the Rapamune ar...
    Medical condition: Renal Transplantation
    Disease: Version SOC Term Classification Code Term Level
    17.1 10042613 - Surgical and medical procedures 10038533 Renal transplant PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-000743-29 Sponsor Protocol Number: 2142002 Start Date*: 2009-07-02
    Sponsor Name:Heads Study Group
    Full Title: Treatment of patients with post-transplant lymphoproliferative disorder (PILD) with a sequential treatment consisting of anti-CD20 antibody rituximab and CHOP + GCSF chemotherapy (including first, ...
    Medical condition: Post-tranplant lymphoproliferative disorder (PTLD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012818 Diffuse large B-cell lymphoma LLT
    Population Age: Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016966-97 Sponsor Protocol Number: CAD01 Start Date*: 2010-06-08
    Sponsor Name:Universitätsklinikum Essen
    Full Title: Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized, Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients with Cold Agglutinin Disease ...
    Medical condition: Cold agglutinin disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009868 Cold type haemolytic anaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002692-16 Sponsor Protocol Number: APL-B-012-02 Start Date*: 2004-10-27
    Sponsor Name:PharmaMar SA unipersonal
    Full Title: A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory Indolent Non-Hodgkin’s Lymphoid Neoplasms.
    Medical condition: Non-Hodgkin’s Lymphomas (NHLs) relapsing or refractory
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 21:02:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA